Rznomics: FDA RMAT Designation and $1.9B Lilly Deal Highlight Pipeline Progress, Operating Loss Widens

RZ-001 (hepatocellular carcinoma) received FDA Regenerative Medicine Advanced Therapy (RMAT) designation, expected to accelerate development
Signed research collaboration and license agreement with Eli Lilly for hereditary hearing loss (total up to $1.334B), joint research ongoing
RZ-001 (glioblastoma) granted FDA Orphan Drug Designation (ODD) and Fast Track, Expanded Access Program approved
RZ-004 (retinitis pigmentosa) obtained IND approval for Phase 1/2a in Australia (TGA)
Q1 2026 revenue of KRW 366 million (research service revenue), compared to zero in prior year period
Operating loss widened to KRW 7.76 billion (vs KRW 5.26 billion in Q1 2025), R&D expenses surged to KRW 7.48 billion (vs KRW 2.88 billion)
Total cash and short-term financial assets of KRW 54.8 billion, no borrowings
Listed on KOSDAQ in December 2025; all convertible preferred shares converted to common shares
Secured core patents for self-circularizing RNA platform, pipeline development underway